Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
- LETI-101 has demonstrated therapeutically relevant reductions of mutant huntingtin (HTT) protein, exceeding 80%, while preserving essential wild-type HTT in a clinically relevant Huntington’s...
-
ElevateBio will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 10:00 a.m. PST.
-
ElevateBio Appoints Amy Pooler, Ph.D., as Life Edit’s Senior Vice President, Research and Development
-
ElevateBio Announces Advancements of its Proprietary Lipid Nanoparticle (LNP) Delivery Platform with Liver Targeting and De-Targeting Potential
-
- Issued patents provide protection for multiple of Life Edit’s lead adenine deaminases, base editors, and RNA-guided nucleases with applications in base editing and reverse transcriptase editing - ...